Lori Styles

8.6k total citations · 1 hit paper
95 papers, 4.8k citations indexed

About

Lori Styles is a scholar working on Genetics, Hematology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Lori Styles has authored 95 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 90 papers in Genetics, 52 papers in Hematology and 20 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Lori Styles's work include Hemoglobinopathies and Related Disorders (71 papers), Iron Metabolism and Disorders (26 papers) and Chronic Lymphocytic Leukemia Research (19 papers). Lori Styles is often cited by papers focused on Hemoglobinopathies and Related Disorders (71 papers), Iron Metabolism and Disorders (26 papers) and Chronic Lymphocytic Leukemia Research (19 papers). Lori Styles collaborates with scholars based in United States, United Kingdom and Canada. Lori Styles's co-authors include Elliott Vichinsky, Frans A. Kuypers, Sandra Larkin, Carolyn Hoppe, Elizabeth C. Wright, Oswaldo Castro, Linda H. Colangelo, Bruce G. Nickerson, Claudia R. Morris and Nigel S. Key and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Lori Styles

94 papers receiving 4.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

2018 380 citations Carol Moreno, Richard Greil et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Lori Styles

Since Specialization

Citations

This map shows the geographic impact of Lori Styles's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lori Styles with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lori Styles more than expected).

Fields of papers citing papers by Lori Styles

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lori Styles. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lori Styles. The network helps show where Lori Styles may publish in the future.

Co-authorship network of co-authors of Lori Styles

This figure shows the co-authorship network connecting the top 25 collaborators of Lori Styles. A scholar is included among the top collaborators of Lori Styles based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lori Styles. Lori Styles is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	1504TiP HARMONi: Randomized, double-blind, multi-center, phase III clinical study of ivonescimab or placebo combined with pemetrexed and carboplatin in patients with EGFR-mutant locally advanced or metastatic non-squamous NSCLC who have progression following EGFR-TKI treatment 2023 ·Annals of Oncology ·Wenfeng Fang, (unknown), (unknown), Yuanyuan Zhao, Yan Huang, Ian C. Anderson, J. Remon Masip, Wenbin Li, Xia Mao, Jing Li, Danelle F. James, Lori Styles, Howard West, L. Zhang	0
2	Ibrutinib Treatment of Pediatric Chronic Graft-versus-Host Disease: Primary Results from the Phase 1/2 iMAGINE Study 2022 ·Transplantation and Cellular Therapy ·Paul A. Carpenter, Hyoung Jin Kang, Keon Hee Yoo, Marco Zecca, Bin Cho, Giovanna Lucchini, Eneida R. Nemecek, Kirk R. Schultz, Polina Stepensky, Sonali Chaudhury, Benjamin Oshrine, Seong Lin Khaw, Andrew C. Harris, (unknown), (unknown), (unknown), Justin T. Wahlstrom, Lori Styles, Peter J. Shaw, Jean‐Hugues Dalle	18
3	Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study 2021 ·Annals of Hematology ·Richard Greil, Alessandra Tedeschi, Carol Moreno, Bertrand Anz, Loree Larratt, Martin Šimkovič, Devinder Gill, John G. Gribben, Ian W. Flinn, Zhengyuan Wang, Leo W.K. Cheung, Aaron Nguyen, Cathy Zhou, Lori Styles, Fatih Demırkan	9
4	Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study 2019 ·Biology of Blood and Marrow Transplantation ·Edmund K. Waller, David B. Miklos, Corey Cutler, Mukta Arora, Madan Jagasia, Iskra Pusic, Mary E.D. Flowers, Aaron C. Logan, Ryotaro Nakamura, Stephen Chang, Fong Clow, Indu Lal, Lori Styles, Samantha Jaglowski	66
5	Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma 2018 ·Clinical Lymphoma Myeloma & Leukemia ·Susan O’Brien, Peter Hillmen, Steven Coutré, Paul M. Barr, Graeme Fraser, Alessandra Tedeschi, Jan A. Burger, Marie‐Sarah Dilhuydy, Georg Heß, Carol Moreno, Paula Cramer, Emily Liu, Stephen Chang, Jessica Vermeulen, Lori Styles, Angela Howes, Danelle F. James, (unknown), Thorsten Graef, (unknown)	63
6	Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial breakdown → 2018 ·The Lancet Oncology ·Carol Moreno, Richard Greil, Fatih Demırkan, Alessandra Tedeschi, Bertrand Anz, Loree Larratt, Martin Šimkovič, Olga Samoilova, Jan Novák, Dina Ben‐Yehuda, Владимир Стругов, Devinder Gill, John G. Gribben, Emily Hsu, Chih‐Jian Lih, Cathy Zhou, Fong Clow, Danelle F. James, Lori Styles, Ian W. Flinn	380
7	Improvement in hematologic function, disease burden/symptoms with ibrutinib in older treatment-naive (TN) patients with chronic lymphocytic leukemia (CLL) in phase 3 RESONATE-2 (TM) 2016 ·Journal of the American Geriatrics Society ·(unknown), Thomas J. Kipps, Tadeusz Robak, Alessandra Tedeschi, Carolyn Owen, Paolo Ghia, Peter Hillmen, Fritz Offner, Carol Moreno, Cathy Zhou, Lori Styles, JA Burger	1
8	Multicenter Open-Label Phase 2 Study of Ibrutinib in Chronic Graft Versus Host Disease (cGVHD) after Failure of Corticosteroids 2016 ·Blood ·David B. Miklos, Corey Cutler, Mukta Arora, Edmund K. Waller, Madan Jagasia, Iskra Pusic, Mary E.D. Flowers, Aaron C. Logan, Ryotaro Nakamura, Bruce R. Blazar, Yunfeng Li, Indu Lal, Jason A. Dubovsky, Danelle F. James, Lori Styles, Samantha Jaglowski	14
9	Phase 1 Study of the E-Selectin Inhibitor GMI 1070 in Patients with Sickle Cell Anemia 2014 ·PLoS ONE ·Ted Wun, Lori Styles, Laura DeCastro, Marilyn J. Telen, Frans A. Kuypers, Anthony Cheung, William G. Kramer, (unknown), Seungshin Rhee, John L. Magnani, Helen Thackray	52
10	Prasugrel in Children With Sickle Cell Disease 2014 ·Journal of Pediatric Hematology/Oncology ·Lori Styles, Darell Heiselman, (unknown), Brian A. Moser, David S. Small, Joseph A. Jakubowski, Chunmei Zhou, Rupa Redding‐Lallinger, Matthew M. Heeney, Charles T. Quinn, Sohail Rana, Julie Kanter, Kenneth J. Winters	20
11	Autonomic Nervous System Reactivity 2011 ·Nursing Research ·Marsha Treadwell, Abbey Alkon, Lori Styles, W. Thomas Boyce	11
12	Quantification of Analgesic Use in Children With Sickle Cell Disease 2006 ·Clinical Journal of Pain ·Eufémia Jacob, Christine Miaskowski, Marilyn Savedra, Judith Beyer, Marsha Treadwell, Lori Styles	23
13	Changes in intensity, location, and quality of vaso-occlusive pain in children with sickle cell disease 2003 ·Pain ·Eufémia Jacob, Christine Miaskowski, Marilyn Savedra, Judith Beyer, Marsha Treadwell, Lori Styles	50
14	Sickle cell disease 2002 ·Pediatric Clinics of North America ·Jason Fixler, Lori Styles	25
15	Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia 2001 ·The Journal of Pediatrics ·Scott T. Miller, Elizabeth C. Wright, Miguel R. Abboud, Brian Berman, B. Files, Charles D. Scher, Lori Styles, Robert J. Adams	175
16	Use of Hydroxyurea in Children Ages 2 to 5 Years With Sickle Cell Disease 2000 ·The American journal of pediatric hematology/oncology ·Carolyn Hoppe, Elliott Vichinsky, Keith Quirolo, (unknown), Katrina J. Allen, Lori Styles	40
17	Hydroxyurea and sodium phenylbutyrate therapy in thalassemia intermedia 1999 ·American Journal of Hematology ·Carolyn Hoppe, Elliott Vichinsky, Bradley Lewis, Dru Foote, Lori Styles	47
18	The Hemoglobin E Syndromes 1998 ·Annals of the New York Academy of Sciences ·David C. Rees, Lori Styles, Elliott Vichinsky, J. B. Clegg, D. J. Weatherall	75
19	Core decompression in avascular necrosis of the hip in sickle-cell disease 1996 ·American Journal of Hematology ·Lori Styles, Elliott Vichinsky	66
20	PULMONARY COMPLICATIONS 1996 ·Hematology/Oncology Clinics of North America ·Elliott Vichinsky, Lori Styles	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact